Publications, Pharmaceutical

Why it is time to think differently about Nasal delivery of Biologics

COVID-19 has reinvigorated interest in the advantages of nasal delivery for a pharmaceutical industry already embracing a shift towards biologics.

Download Publication
Author(s): Gemma Budd Irene Rossi
4 Apr 2022

This article considers the challenges and potential benefits of combining the two. The nasal delivery of biologics offers considerable potential for both local and systemic action and for direct access to the brain and CNS to address currently unmet therapeutic need. The unique features of biologics are discussed with reference to the associated difficulties of nasal delivery and the benefits of partnership with experts such as Aptar Pharma is highlighted. Work on the development of vaccines and prophylactics for COVID-19 illustrates what is achievable.

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More About nasal drug delivery expertise

This Might Also Be of Interest

28 Apr 2021

Using Raman for the characterization of nasal drug suspension products

Publications, Pharmaceutical, Innovation & Insights, Drug Delivery Innovations, Product Solutions

Read More
27 Apr 2021

The New Imperative

Publications, Pharmaceutical, Drug Delivery Innovations, Market Insights, Product Solutions, Innovation & Insights

Read More
22 Apr 2021

Case Study – Pre-Clinical Respiratory Research with PADA

Case Studies, Pharmaceutical, Product Solutions, Innovation & Insights, Drug Delivery Innovations

Read More
25 Mar 2021

Intranasal Immunization: Promises and Challenges

Webinars, Pharmaceutical, Market Insights, Product Solutions, Sustainability, Innovation & Insights, Drug Delivery Innovations

Read More
1 18 19 20 21 22 27

Request Access

Close

Requesting access to Why it is time to think differently about Nasal delivery of Biologics.

  • This field is for validation purposes and should be left unchanged.
Back To Top